Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer

Cell division associated 1 (CDCA1) was screened as an oncogene that is overexpressed on several cancers, including prostate cancer. A highly immunogenic HLA‐A*2402‐restricted epitope peptide corresponding to part of the CDCA1 protein was also identified. A phase I clinical trial was conducted for pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Obara, Wataru, Sato, Fuminori, Takeda, Kazuyoshi, Kato, Renpei, Kato, Yoichiro, Kanehira, Mitsugu, Takata, Ryo, Mimata, Hiromitsu, Sugai, Tamotsu, Nakamura, Yusuke, Fujioka, Tomoaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497926/
https://www.ncbi.nlm.nih.gov/pubmed/28498618
http://dx.doi.org/10.1111/cas.13278

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497926/
https://www.ncbi.nlm.nih.gov/pubmed/28498618
http://dx.doi.org/10.1111/cas.13278

Ejemplares similares